Short communication: Decrease in mitochondrial transmembrane potential in peripheral blood mononuclear cells of HIV-uninfected subjects undergoing HIV postexposure prophylaxis

AIDS Research and Human Retroviruses

Volumn 27, Issue 9, 2011, Pages 969-972

  Groener, Jan B ^a   Seybold, Ulrich ^a   Vollbrecht, Thomas ^a   Bogner, Johannes R ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR;

ADULT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MITOCHONDRION; PERIPHERAL BLOOD MONONUCLEAR CELL; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; APOPTOSIS; CHEMOPREVENTION; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE POTENTIALS; MIDDLE AGED; MITOCHONDRIAL MEMBRANES; POST-EXPOSURE PROPHYLAXIS; STAINING AND LABELING;

EID: 80052059796     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0348     Document Type: Article

References (16)

1. Foli A, Benvenuto F, Piccinini G, et al.: Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS 2001; 15(13):1687-1694. (Pubitemid 32918123)
2. Lewis W, Day BJ, and Copeland WC: Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective. Nat Rev Drug Discov 2003;2(10):812-822. (Pubitemid 37361813)
3. Lopez S, Negredo E, Garrabou G, et al.: Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. AIDS Res Hum Retroviruses 2006;22(1):33-39. (Pubitemid 43201515)
4. Walker UA, Auclair M, Lebrecht D, Kornprobst M, Capeau J, and Caron M: Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006;11(1):25-34.
5. Lugli E, Troiano L, Ferraresi R, et al.: Characterization of cells with different mitochondrial membrane potential during apoptosis. Cytometry A 2005;68(1):28-35. (Pubitemid 41572060)
6. Birkus G, Hitchcock MJ, and Cihlar T: Assessment of mito-chondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46(3):716-723. (Pubitemid 34157656)
7. Venhoff N, Setzer B, Melkaoui K, and Walker UA: Mi-tochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 2007;12(7):1075-1085. (Pubitemid 350114988)
8. Negredo E, Miro O, Rodriguez-Santiago B, et al.: Improvement of mitochondrial toxicity in patients receiving a nucle-oside reverse-transcriptase inhibitor-sparing strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin Infect Dis 2009;49(6):892-900.
9. Sternfeld T, Schmid M, Tischleder A, et al.: The influence of HIV infection and antiretroviral therapy on the mitochon-drial membrane potential of peripheral mononuclear cells. Antivir Ther 2007;12(5):769-778. (Pubitemid 47235491)
10. Mallon PW, Unemori P, Sedwell R, et al.: In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mi-tochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005;191(10): 1686-1696. (Pubitemid 40656757)
11. Cossarizza A: Tests for mitochondrial function and DNA: Potentials and pitfalls. Curr Opin Infect Dis 2003;16(1):5-10. (Pubitemid 36205249)
12. Salvioli S, Ardizzoni A, Franceschi C, and Cossarizza A: JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: Implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997;411(1):77-82. (Pubitemid 27298375)
13. Chaudhari AA, Seol JW, Kang SJ, and Park SY: Mitochon-drial transmembrane potential and reactive oxygen species generation regulate the enhanced effect of CCCP on TRAIL-induced SNU-638 cell apoptosis. J Vet Med Sci 2008;70(6): 537-542. (Pubitemid 352008808)
14. Hodge GL, Flower R, and Han P: Optimal storage conditions for preserving granulocyte viability as monitored by Annexin V binding in whole blood. J Immunol Methods 1999;225(1-2):27-38. (Pubitemid 29276933)
15. Caso G, Mileva I, McNurlan MA, Mynarcik DC, Darras F, and Gelato MC: Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation. Antiviral Res 2010;86(2):137-143.
16. Widlansky ME, Wang J, Shenouda SM, et al.: Altered mito-chondrial membrane potential, mass, and morphology in the mononuclear cells of humans with type 2 diabetes. Transl Res 2010;156(1):15-25.